Valuation: Inhalation Sciences Sweden AB

Market Cap 7.83M 817K 709K 665K 606K 1.14M 77.91M 1.16M 3.05M 39.12M 3.07M 3M 131M P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 5M 522K 453K 425K 387K 728K 49.75M 739K 1.95M 24.98M 1.96M 1.92M 83.87M EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
94.25%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 2019-09-15
Chief Tech/Sci/R&D Officer - 2004-12-31
Corporate Officer/Principal - 2025-06-01
Director TitleAgeSince
Director/Board Member - 2004-12-31
Director/Board Member - 2022-08-31
Director/Board Member - 2024-08-31
Change 5-day change 1-year change 3-year change Capi.($)
+6.90%-.--% - - 899K
-0.33%+6.77%+30.41%+10.89% 224B
-0.80%+5.65%+3.02%-19.43% 146B
+0.01%+8.96%-14.96%+31.78% 142B
+0.45%+4.75%-49.96%+0.76% 74.19B
-0.65%+3.85%+19.05%+17.18% 53.99B
-1.41%+0.08%-14.95%-17.29% 50.85B
-0.84%+6.49%+29.89%+16.85% 42.22B
+0.28%+5.07%+49.00%+42.68% 40.75B
-0.65%+2.88%-0.99%+0.96% 32.86B
Average +0.39%+5.30%+5.61%+9.38% 89.57B
Weighted average by Cap. -0.33%+6.23%+6.09%+8.31%

Financials

2024 2025
Net sales 11.05M 1.15M 1M 938K 854K 1.61M 110M 1.63M 4.3M 55.18M 4.33M 4.23M 185M 3.04M 317K 275K 258K 235K 443K 30.25M 449K 1.18M 15.19M 1.19M 1.17M 50.99M
Net income -5.15M -537K -466K -437K -398K -749K -51.19M -761K -2.01M -25.71M -2.02M -1.97M -86.3M -10.16M -1.06M -920K -863K -786K -1.48M -101M -1.5M -3.96M -50.75M -3.98M -3.89M -170M
Net Debt -4M -418K -362K -340K -310K -583K -39.81M -592K -1.56M -19.99M -1.57M -1.53M -67.12M -2.83M -295K -256K -240K -219K -412K -28.16M -418K -1.1M -14.14M -1.11M -1.08M -47.47M
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
-

Net sales - Rate of surprise